NCT01479387View on ClinicalTrials.gov

Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan

CompletedOBSERVATIONAL
Enrollment

72

Participants

Timeline

Start Date

August 31, 2008

Study Completion Date

February 28, 2011

Conditions
Non-Hodgkin's Lymphoma (NHL)
Interventions
DRUG

[111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)

Patients who have received In-111 Zevalin.

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY